International Study Highlights Need to Support Patients With Psoriasis Suffering Feelings of Isolation, Stigmatisation and Anxiety

COPENHAGEN, Denmark--1 Oct--PRNewswire/InfoQuest


- LEO Pharma has conducted the first truly large scale international study informed by both qualitative and quantitative data to investigate the impact of psoriasis

- The findings reveal that feelings of restriction, isolation, stigmatisation and anxiety are associated with a high impact on patients' lives; and are more important than diagnosed symptom severity

Data from the Burden of Psoriasis patient research were presented this weekend at the 21st EADV Congress in Prague, Czech Republic. The results from the research, which included a quantitative online survey completed by 3,822 patients with psoriasis, showed 73% of patients surveyed scored their psoriasis as having a moderate to high impact on their lives[1].

To view the Multimedia News Release, please click:

http://multivu.prnewswire.com/mnr/prne/leo-pharma/56611

People living with psoriasis experience flare-ups that can result in the appearance of thick, red, scaly skin lesions on any part of their body[2]. The skin is often sore and itchy [2],[ 3], but the current study emphasizes that the psychological impact of psoriasis can have an even greater impact on patients' everyday lives[1].

Factors analysed in the research included the influence of symptom burden, healthcare professional (HCP) relationships, patient factors and the psychosocial impact of psoriasis on how much the patient's psoriasis "dictates how they live their life"[1]. Factors that were most strongly associated dealt with daily activities, stigmatisation, isolation and anxiety. However, diagnosed symptom severity was not a significant indicator[1].

Commenting on the research Dr Anthony Bewley, Whipps Cross University Hospital & Barts & the London NHS Trust, UK, said, "The reality for patients is that the reactions of other people, real or perceived, can make life a real struggle. We need to ensure that we actively question our patients about these issues, and modify management accordingly. We plan further analysis of this comprehensive data set, which we believe will help to individualise care".

"The physical, psychological and social effects of psoriasis can have a serious impact on people's lives," said LEO Pharma President and CEO Gitte P. Aabo. "To give people with psoriasis the best chance of improving their quality of life, we need to address the issues that affect them individually. The Burden of Psoriasis patient research will help healthcare professionals learn more about the impact that psoriasis has on peoples' lives and hence inform and help evolve the way the disease is treated."

References

1. Bewley A, Ersser S, Hansen M, Pevac C. Psychosocial and symptomatic burden of psoriasis for patients in Europe, the USA and Canada. Abstract presented at: EADV Congress, Prague, 27 - 30 September 2012 (ID number PRA12-0920).

2. Basavaraj KH, Navya MA, Rashmi R. Stress and quality of life in psoriasis: an update. Int J Dermatol 2011;50:783-92.

3. A.D.A.M. Medical Encyclopedia. Psoriasis. (Accessed May, 2012, at http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001470/ .)

Source: LEO Pharma

-PM-

ข่าวLEO Pharma+o:healวันนี้

LEO Pharma Enters Biologics Through Strategic Partnership With AstraZeneca

LEO Pharma is a significant step closer to realising its vision of becoming the preferred dermatology care partner following a strategic partnership with AstraZeneca announced today. (Logo: http://photos.prnewswire.com/prnh/20130221/595427 ) The partnership covers potential new medicines for atopic dermatitis and psoriasis, two of the world's major skin diseases where a significant unmet medical need remains. With the partnership, LEO Pharma enters into biological medicines within dermatology

LEO Pharma Receives Scientific Approval of Enstilar(R) for the Treatment of Psoriasis in EU

The marketing approval of Enstilar(R) would make it the first fixed combination topical foam treatment for people living with psoriasis vulgaris in the EU. LEO Pharma today announced that it received...

LEO Pharma Announces US Regulatory Submission of the First Aerosol Foam for Psoriasis

Not Intended for US Media LEO Pharma announced it has submitted a New Drug Application to the US Food and Drug Administration (FDA) for calcipotriene/betamethasone dipropionate aerosol foam 0,005%/0,064% for the...

ลีโอ ฟาร์มา ยึดผู้ป่วยเป็นศูนย์กลางการพัฒนานวัตกรรมรักษาโรคสะเก็ดเงิน

ลีโอ ฟาร์มา (LEO Pharma) ผู้นำด้านโรคผิวหนัง ประกาศทำข้อตกลงร่วมสร้างสรรค์นวัตกรรมกับมูลนิธิโรคสะเก็ดเงินแห่งชาติ (National Psoriasis Foundation: NPF) ในสหรัฐอเมริกา เพื่อยึดผู้ป่วยเป็นศูนย์กลางในการพัฒนานวัตกรรมของบริษัท...

LEO Pharma Puts Patients at the Heart of Innovation

LEO Pharma announces a co-creation agreement with the National Psoriasis Foundation (NPF) in the United States that puts patients at the heart of LEO Pharma's innovation process. The move supports the dermatology company's aim to develop future care...

Virobay and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis

Virobay, Inc. and LEO Pharma A/S today announced that their collaboration on the development of an oral treatment for psoriasis has reached an important milestone as Virobay has now...

ลีโอ ฟาร์มา และโฟร์เอสซี ดิสคัฟเวอรี่ ประกาศทำข้อตกลงการวิจัยและการอนุญาตใช้สิทธิ์

ลีโอ ฟาร์มา เอ/เอส (LEO Pharma A/S) บริษัทเวชภัณฑ์ชั้นนำของโลกที่มีความเชี่ยวชาญด้านผิวหนังวิทยา ได้บรรลุข้อตกลงการวิจัยและการอนุญาตใช้สิทธิ์กับ โฟร์เอสซี ดิสคัฟเวอรี่ จีเอ็มบีเอช (4SC Discovery GmbH) บริษัทด้านเทคโน...

LEO Pharma and 4SC Discovery Announce Exclusive Research and License Agreement

LEO Pharma A/S, a global pharmaceutical company specialising in dermatology, has entered into an exclusive research and license agreement with the German biotech company 4SC Discovery GmbH with the primary aim of jointly...

PsorCARE Program by LEO Pharma Asia Focuses on Treatment Adherence to Improve Psoriasis Treatment Outcomes

Psoriasis is a little-understood skin condition that carries a strong social stigma through its emotional impact on sufferers that can far outweigh the disease's physical impact. That is why...

Picato(R) Gel Receives EU Marketing Authorisation for Treatment of Actinic Keratosis

Today LEO Pharma announced that the European Commission (EC) has granted marketing authorisation for Picato(R) (ingenol mebutate) gel as a treatment for actinic keratosis in the European Union (EU). Picato(R) gel is...